International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.
Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.
Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.
Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.
An International Open Access Journal Devoted to General Medicine.
Adenoid cystic carcinoma (ACC) is a rare malignant tumor that arises primarily in exocrine glands, most commonly in the salivary glands. Despite its relatively low incidence, accounting for 1% of head and neck malignancies, 4% of salivary gland tumors and 7.5% of all epithelial salivary gland malignancies, ACC is characterized by its aggressive biological behavior, including perineural infiltration, a high recurrence rate and a propensity for distant metastases (1). The standard treatment for ACC consists of surgical resection followed by adjuvant radiotherapy and, in some cases, cytotoxic chemotherapy. However, recurrence or metastases occur in >50% of cases, rendering the disease difficult to cure and leading to poor long-term survival rates of 68% at 5 years, 52% at 10 years and 28% at 20 years (1,2).
Molecular research has gradually identified the oncogenic mechanisms underlying ACC, largely facilitated by whole-exome sequencing and whole-genome sequencing. One of the most notable discoveries is the MYB:NFIB gene fusion, resulting from the t(6;9) translocation; this alteration is frequently observed in ACC and often leads to upregulation of MYB oncoproteins, which promote tumor proliferation. However, direct or indirect therapeutic targeting of MYB remains challenging and has not yet produced major clinical breakthroughs (3,4). Other molecular markers, such as KIT proto-oncogene, receptor tyrosine kinase (KIT; also known as CD117), fibroblast growth factor receptor 1 (FGFR1), epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), have been explored as potential therapeutic targets (2). Although inhibitors, such as imatinib for KIT, dovitinib for FGFR1 and various VEGF receptor (VEGFR) inhibitors, have been tested in clinical trials not only in head and neck squamous cell carcinoma, but also in ACC, their efficacy in ACC remains limited (3).
Although immunotherapy has revolutionized treatment in several types of solid tumors, its efficacy in ACC has been limited. Clinical trials evaluating immune checkpoint inhibitors, such as programmed cell death protein 1/programmed death-ligand 1 (PD-L1) blockade, have shown disappointing results in ACC, likely due to the low mutational burden and limited immune cell infiltration of the tumor. Similarly, MYB-directed vaccine strategies, particularly the TetMYB DNA vaccine combined with anti-PD-1 therapy in the phase I MYPHISMO study (NCT03287427), remain investigational in metastatic ACC, and clinical benefit has not yet been established (5). These findings highlight the need for alternative precision medicine strategies in ACC, such as molecular profiling to identify potentially actionable molecular alterations and inform individualized treatment considerations (6).
Given the rarity and heterogeneity of ACC, defining precise prognostic and predictive markers remains challenging. While molecular insights continue to expand, effective systemic therapies remain lacking, underscoring the need for further translational research to identify viable treatment strategies to improve patient outcomes. Comprehensive genomic profiling approaches, including next-generation sequencing (NGS), have contributed to this effort; however, their routine clinical application in rare tumors such as ACC remains limited by cost, tissue requirements, turnaround time and the scarcity of validated predictive biomarkers. By contrast, immunohistochemistry-based protein panels offer a pragmatic and widely accessible strategy for protein-level assessment of markers related to potential therapeutic targets. To date, however, predefined immunohistochemistry-based panels systematically applied to guide real-world systemic therapy decisions in metastatic ACC have been rarely reported (3).
The present study aimed to evaluate the feasibility and translational applicability of a predefined immunohistochemistry-based 11-protein panel in the molecular characterization of advanced ACC in an exploratory, real-world setting, with the objective of supporting drug repurposing strategies using agents originally approved for other oncological indications.
The present study was conducted as an ACC-focused post hoc analysis of tissue samples and associated clinical data that had been prospectively collected at a tertiary referral center. The ACC cases analyzed in the current study were previously included within a broader heterogeneous cohort reported by Doescher et al (2019) (3), which focused on the methodological feasibility of the protein panel across multiple tumor entities. The present study provides a dedicated ACC-focused analysis with extended clinical follow-up and disease-specific interpretation. Ethics approval was obtained from the Ethics Committee of Ulm University (approval no. 90/15; June 2015; Ulm, Germany). All participants provided written informed consent in connection with their inclusion in the institutional biobank and for the prospective collection and subsequent scientific analysis of their tissue samples and associated clinical data. The present investigation represents a post hoc analysis of these prospectively collected samples and data.
All samples were formalin-fixed and paraffin-embedded following standard protocols. ACC diagnosis adhered to World Health Organization guidelines (7,8) and was confirmed by at least two board-certified pathologists. Panel testing was recommended by the multidisciplinary tumor board, which included specialists in head and neck surgery, maxillofacial surgery, medical oncology, radiation oncology, radiology and pathology. The results were then reviewed by the board, and a panel-based treatment recommendation was issued.
The predefined immunohistochemistry-based protein panel comprised antibodies targeting 11 proteins: EGFR, MET proto-oncogene, receptor tyrosine kinase (MET), human epidermal growth factor receptor 2 (HER2), anaplastic lymphoma kinase (ALK), vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), FLI1, KIT/CD117, androgen receptor (AR), TNFR8/CD30 and programmed death-ligand 1 (PD-L1) (Fig. 1). Together, the panel defines an 11-protein expression signature associated with key oncogenic pathways. These specific proteins were selected based on their applicability and availability in routine diagnostics, and/or their established prognostic or predictive relevance in tumors other than ACC.
The ACC samples were stained in parallel with the cases from the previously published protein-panel cohort, using the same antibody panel and staining conditions (3,9). Formalin-fixed, paraffin-embedded tissue microarray (TMA) sections were stained on the Dako Omnis platform (Dako, Glostrup, Denmark). Appropriate marker-specific positive and negative control tissues were included. Immunolabeling was visualized using alkaline phosphatase- or immunoperoxidase-based detection systems. The available antibody specifications, including host species, clonality, clone, manufacturer, catalogue number where documented, working dilution, and expected staining localization, are provided in Table I.
Cases were classified as positive when >10% of tumor cells exhibited immunoreactivity in the appropriate cellular compartment. HER2 immunohistochemical scoring was performed according to established American Society of Clinical Oncology/College of American Pathologists criteria, applying a semi-quantitative scale from 0 to 3+, with scores of 2+ or 3+ classified as positive according to the original panel protocol. No universally established ACC-specific scoring systems exist for the remaining markers; therefore, these markers were evaluated using the predefined criteria of the original protein-panel protocol (3,9).
Because staining intensity and exact percentages of positive tumor cells were not available in a complete, harmonized retrospective dataset for all cases, results are reported descriptively using the predefined positivity threshold. Formal inter-observer variability was not assessed. All images were captured using an Olympus BX51 microscope connected to a digital camera or a whole-slide scanning system (Olympus Soft Imaging Solutions GmbH) (3,9).
The analysis was performed using archived TMA material, and whole-section staining was not systematically performed. The TMA-based approach enabled standardized, tissue-sparing assessment across the available cohort; however, it may not fully capture intratumoral heterogeneity in therapeutically relevant biomarkers. This limitation was considered when interpreting marker positivity.
No formal statistical analysis was performed due to the small sample size and the exploratory nature of the study; therefore, data are presented descriptively. The UpSet plot was generated using R software (version 4.5.0; R Foundation for Statistical Computing) with RStudio (version 2024) (10).
Between January 2014 and November 2024, 10 patients with advanced-stage, recurrent and/or metastatic ACC were treated at the Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital of Ulm. All cases were discussed by the multidisciplinary tumor board due to progressive disease and limited standard systemic treatment options. Of these, seven underwent panel testing analysis and constitute the profiled study cohort. Because the cohort was identified retrospectively across an extended real-world treatment interval, the reasons for not performing panel testing in the remaining three patients were not consistently documented in the available records.
Two patients were male and eight were female, with an age range of 48–84 years. The primary tumor was located in the nasal cavity/paranasal sinuses in three patients, in the submandibular gland in three patients, in the soft palate in three patients and in the base of the tongue in one patient. No predefined clinical selection criteria were applied for protein panel testing.
Based on the panel findings, treatment recommendations were issued for six of the seven profiled patients (Table II). In one additional patient, systemic therapy was initiated without prior panel-based guidance. Not all recommended therapies were ultimately initiated, and treatment implementation and follow-up varied across this real-world cohort. Accordingly, systematic response assessment using uniform criteria such as Response Evaluation Criteria in Solid Tumors was not consistently feasible, and formal analyses of response rate, progression-free survival (PFS) or overall survival (OS) were not performed.
The most frequently detected markers were EGFR and MET, with each of these proteins expressed in four out of seven profiled patients (57%). PDGFR and KIT were detected in three patients each (43%), and low-level HER2 expression was observed in one patient (14%).
As illustrated in the UpSet plot (Fig. 2), four tumors expressed MET: two in combination with EGFR, one with PDGFR, and one with low-level HER2 expression. Four tumors expressed EGFR overall: two with MET, one with PDGFR, and one with KIT and PDGFR. KIT and PDGFR were each expressed in three tumors. Low-level HER2 expression was observed in one tumor in combination with MET. The remaining panel markers (ALK, VEGFR, FLI1, AR, TNFR8/CD30 and PD-L1) were either uniformly negative or exhibited no clinically relevant expression patterns in this cohort.
Systemic treatment recommendations included gefitinib for EGFR-positive cases, lenvatinib for co-expression of EGFR and MET, imatinib for isolated KIT positivity, trastuzumab-deruxtecan for low-level HER2 with MET expression, and axitinib for combined EGFR, PDGFR and KIT expression patterns. In one case (patient 6), axitinib was recommended empirically in the absence of molecular profiling.
One illustrative case is a 64-year-old woman with EGFR-positive ACC of the sphenoid sinus, initially diagnosed in 2018. Following molecular profiling in 2021, the patient received gefitinib due to strong EGFR upregulation, and experienced sustained disease stability for ~3 years before systemic progression occurred in late 2024. This case is presented as an illustrative, hypothesis-generating example of translational applicability rather than as evidence of treatment efficacy.
The prognosis for advanced ACC with distant metastases remains unfavorable. In recent years, small-molecule inhibitors and targeted therapies, such as tyrosine kinase inhibitors (TKIs), have been introduced for the treatment of ACC. However, to the best of our knowledge, no randomized controlled trials have been conducted to compare survival outcomes across different systemic targeted therapies. Studies of targeted therapies tend to be more homogeneous than chemotherapy trials, which often include multiple histological subtypes. Due to the rarity of ACC, patient cohorts in these studies are generally small. The following section provides more details and an overview of therapeutic options (Table III).
Table III.Summary of selected targeted therapies evaluated in clinical studies for salivary gland cancer, including the number of patients enrolled, molecular targets and reported response rates. |
Given that VEGFR expression is observed in ~76% of ACC cases, and is associated with recurrence and metastasis (11), multiple phase II studies have evaluated VEGFR inhibitors. Agents tested include lenvatinib (VEGFR, FGFR, PDGFR), axitinib (VEGFR, PDGFR, KIT) and apatinib (VEGFR, PDGFR, KIT) (12–14). Axitinib and lenvatinib have been reported to yield objective response rates (ORRs) of 8–16%. These agents, which have demonstrated the highest ORRs among TKIs, are discussed in greater detail in the present study.
ACC is characterized by high KIT expression, which has been reported in ≤90% of cases. Based on this, imatinib, an inhibitor of KIT, bcr-abl and PDGFRA, has been tested in several phase II studies (15–17); however, it has failed to demonstrate significant efficacy in ACC. When combined with cisplatin, the combination has achieved a partial response (PR) in 10% of patients. In the present cohort, three of seven patients who underwent protein panel testing were KIT-positive, confirming the frequent molecular expression of this target in clinical practice.
Immunohistochemical studies have also reported EGFR upregulation in ACC (18). Consequently, several phase II trials have investigated EGFR inhibitors, including cetuximab (19) and gefitinib (20). Despite a clinical benefit rate of 50% for cetuximab, regardless of EGFR expression or copy number gain, none of the EGFR inhibitors have shown significant ORR improvements.
Although several agents have shown promising preclinical activity in ACC by targeting altered molecular pathways, clinical results have remained inconsistent among the drugs that have advanced to clinical trials. In this scenario, drug repurposing, a strategy aimed at identifying new therapeutic applications for already approved drugs, remains a relevant therapeutic approach. Drug repurposing can markedly reduce the costs of developing new treatments and accelerate the supply of new therapies for diseases that are difficult to treat, such as ACC.
Locati et al (12) investigated axitinib in 26 patients, reporting an ORR of 8% (all PR), a stable disease (SD) rate of 50% and a disease progression (DP) rate of 42%. The median PFS was 5.5 months and OS reached 26.2 months. Patients received 10 mg axitinib daily, and common adverse events included stomatitis, fatigue and hypertension. Another study by Ho et al (21) examined axitinib at a daily dose of 10–20 mg in 33 patients, reporting an ORR of 9.1% (all PR), an SD rate of 75.8% and a DP rate of 12.1%. The median PFS was 5.7 months. Adverse events included hypertension, oral pain and fatigue. Notably, the second study also incorporated MYB biomarker analysis and genomic profiling. Based on their findings, Locati et al (12) concluded that axitinib is not a viable treatment for ACC, whereas Ho et al (21) suggested that patients with 4q12-amplified ACC may benefit from TKI therapy.
Apatinib is a novel, orally active small-molecule TKI that selectively and potently inhibits VEGFR-2; by targeting VEGFR-2, it effectively suppresses VEGF-mediated endothelial cell migration and proliferation. Preclinical studies and clinical trials have demonstrated its promising antitumor activity and manageable safety profile (22). Zhu et al (14) conducted a single-arm, phase II study evaluating apatinib in 65 patients with recurrent or metastatic ACC of the head and neck. The ORR was 46.2% (all PR) and the disease control rate reached 98.5%. Median PFS was not explicitly stated, but the 6-, 12- and 24-month PFS rates were 92.3, 75.2 and 44.7%, respectively. The median duration of response was 17.7 months, and OS rates at 12 and 24 months were 92.3 and 82.3%, respectively. The most common grade 3–4 adverse events were proteinuria (9.2%), hypertension (5.9%) and hemorrhage (5.9%); notably, one patient experienced a treatment-related fatal hemorrhage. These results suggest that apatinib has promising clinical activity and manageable toxicity in this patient population.
Tchekmedyian et al (13) evaluated lenvatinib in 33 patients with ACC. The ORR was 15.6% (all PR), with an SD rate of 75% and a median PFS of 17.5 months. Adverse events included hypertension and oral pain. Notably, 6.3% of patients discontinued treatment due to toxicity before the first scan, 23 patients required dose reductions and 56.3% ultimately discontinued lenvatinib due to drug-related effects. Severe grade 4 toxicities included myocardial infarction, posterior reversible encephalopathy syndrome and intracranial hemorrhage.
Another phase II trial by Locati et al (23) assessed lenvatinib in 28 patients with ACC, reporting an ORR of 11.5% (all PR), a median PFS of 9.1 months and a median OS of 27 months. Adverse events such as asthenia, hypertension and weight loss were common; overall, 96% of patients experienced side effects, with 50% classified as grade ≥3. Due to toxicity, dose reductions were necessary in 85.7% of cases.
Prospective evaluations of single-agent and combination cytotoxic chemotherapy have been limited by small patient cohorts, heterogeneous study populations and the absence of control groups (24). Consequently, no high-level evidence supports a survival benefit for chemotherapy in ACC. Nevertheless, some patients exhibit responses, suggesting that cytotoxic agents may be beneficial for reducing tumor burden and controlling symptoms. Notably, most chemotherapy trials included four to six treatment cycles.
Advanced solid tumors may require therapeutic strategies that target multiple pathways, as resistance to a single agent can emerge in tumor subpopulations. Although monotherapy has shown limited activity in large or highly metastatic tumors, combination approaches may warrant further investigation in appropriately designed studies.
To the best of our knowledge, only a few studies have explored predefined immunohistochemistry-based protein panels to inform real-world systemic therapy decisions in metastatic ACC (25). Comprehensive molecular profiling approaches, such as NGS and RNA-based platforms, provide broad genomic characterization and are increasingly integrated into precision oncology frameworks. These methods enable the identification of driver mutations, gene fusions, copy number alterations and complex molecular signatures that may inform targeted therapy or clinical trial eligibility. However, despite their depth of coverage, such approaches may be limited in routine clinical practice by cost, turnaround time, tissue requirements and accessibility, particularly in rare tumor entities such as advanced ACC, where validated predictive biomarkers remain scarce. While NGS represents the current standard for comprehensive molecular profiling, its high cost and tissue requirements often limit routine use. In this context, immunohistochemistry-based protein panels offer a pragmatic, cost-effective and rapid complementary approach for drug repurposing considerations in rare malignancies. Immunohistochemistry-based protein panels offer a pragmatic and widely available strategy for protein-level assessment of markers that may be related to therapeutic targets. While they do not provide comprehensive genomic insights, they may serve as a rapid screening tool to support therapeutic decision-making, particularly for heavily pretreated patients with limited treatment options. Notably, protein expression may be discordant with underlying genomic alterations, and immunohistochemical positivity alone should not be interpreted as a validated predictive biomarker. Rather than replacing genomic profiling, this approach should therefore be viewed as complementary. A combined strategy may be particularly valuable: NGS can enable molecular stratification and clinical trial allocation, whereas immunohistochemistry-based panels can facilitate timely identification of protein-expression patterns within real-world clinical workflows. In metastatic ACC, such integration may support more individualized treatment discussions while preserving clinical feasibility.
The small sample size of the current study inherently limits the statistical power, representativeness and generalizability of the findings. Given the rarity of advanced ACC, this proof-of-concept study was designed as an exploratory, real-world feasibility analysis, rather than a hypothesis-testing investigation, and no inferential statistical conclusions can be drawn from this cohort. Furthermore, a systematic correlation analysis between biomarker expression and treatment response was not feasible in this small, heterogeneous cohort; therefore, the predictive value of individual markers cannot be inferred and requires prospective validation. The single illustrative case in which panel findings coincided with disease stability under EGFR-directed therapy should be interpreted with caution, as no causal inference can be drawn from an uncontrolled, single-patient observation. Additional limitations include the retrospective patient-selection process; incomplete reconstructability of individual testing decisions; the use of TMAs rather than systematic whole-section analysis; the potential for intratumoral heterogeneity; heterogeneous real-world documentation; the absence of formal inter-observer variability assessment; and the absence of standardized response assessment. The lack of tissue obtained at progression further limits the assessment of acquired resistance mechanisms and temporal biomarker dynamics. Future studies integrating immunohistochemistry-based panel assays with comprehensive molecular profiling approaches, such as NGS, may provide a more complete characterization of potentially relevant molecular and protein-expression patterns, and enable a more robust evaluation of their translational relevance in ACC.
In conclusion, using a predefined immunohistochemistry-based 11-protein panel, six out of seven patients with advanced ACC profiled in the present exploratory feasibility study exhibited potentially actionable markers, with EGFR and MET being the most frequently expressed. In one illustrative case, panel findings supported the selection of EGFR-directed therapy and coincided with prolonged disease stability; an observation that, while hypothesis-generating, cannot establish causality given the study design. These findings suggest the operational feasibility of the panel-based approach and its capacity to identify potentially actionable markers in this rare malignancy. Molecular testing to inform drug repurposing represents a promising strategy for further investigation in ACC, where tumor rarity and biological heterogeneity limit the development of evidence-based systemic therapies. Nevertheless, the clinical relevance of protein expression as a predictive biomarker requires prospective validation in larger cohorts, ideally integrated with complementary molecular profiling approaches, such as NGS.
Not applicable.
Funding: No funding was received.
The data generated in the present study are not publicly available due to privacy and legal restrictions under German law but may be requested from the corresponding author.
PJS designed the research. RT and PJS performed clinical data acquisition and confirm the authenticity of all the raw data. TKH and PJS selected patients. SEW contributed to the histopathological and immunohistochemical assessment. AVW, SL and JD analyzed results. JD, AVW, TKH and PJS contributed to the interpretation of the findings and critical revision of the manuscript. RT wrote the manuscript. All authors read and approved the final manuscript.
The study protocol and all experimental procedures were approved by the Ethics Committee of Ulm University, Germany (approval no. 90/15). All participants provided written informed consent for inclusion in the institutional biobank and for the prospective collection and subsequent scientific analysis of their tissue samples and clinical data. The present study represents a post hoc analysis of these prospectively collected samples and data. All procedures were conducted in accordance with the applicable institutional guidelines and regulations.
Not applicable.
The authors declare that they have no competing interests.
During the preparation of this work, AI tools were used to improve the readability and language of the manuscript, and subsequently the authors revised and edited the content produced by the AI tools as necessary, taking full responsibility for the ultimate content of the present manuscript.
|
Spiro RH, Huvos AG and Strong EW: Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg. 128:512–520. 1974. View Article : Google Scholar : PubMed/NCBI | |
|
Chae YK, Chung SY, Davis AA, Carneiro BA, Chandra S, Kaplan J, Kalyan A and Giles FJ: Adenoid cystic carcinoma: Current therapy and potential therapeutic advances based on genomic profiling. Oncotarget. 6:37117–37134. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Doescher J, Weissinger SE, Schönsteiner SS, Lisson C, Bullinger L, Barth TF, Leithäuser F, Mueller-Richter U, Laban S, Hoffmann TK, et al: Clinical utility of a protein-based oncopanel in patients with end-stage head and neck cancer. Immunotherapy. 11:1193–1203. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Wysocki PT, Izumchenko E, Meir J, Ha PK, Sidransky D and Brait M: Adenoid cystic carcinoma: Emerging role of translocations and gene fusions. Oncotarget. 7:66239–66254. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pham T, Pereira L, Roth S, Galletta L, Link E, Akhurst T, Solomon B, Michael M, Darcy P, Sampurno S, et al: First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427). Contemp Clin Trials Commun. 16:1004092019. View Article : Google Scholar : PubMed/NCBI | |
|
Zupancic M, Näsman A, Friesland S and Dalianis T: Adenoid cystic carcinoma, clinical presentation, current treatment and approaches towards novel therapies. Anticancer Res. 44:1325–1334. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Stenman G, Licitra L, Said-Al-Naief N, van Zante A and Yarbrough W: Adenoid cystic carcinoma. WHO Classification of Head and Neck Tumours. World Health Organization Classification of Tumours. El-Naggar AK, Chan JKC, Grandis JR, Takata T and Slootweg PJ: 4th edition. Vol 9. International Agency for Research on Cancer; Lyon: pp. 164–165. 2017 | |
|
Ueda K, Murase T, Nagao T, Kusafuka K, Urano M, Yamamoto H, Nakaguro M, Taguchi KI, Masaki A, Hirai H, et al: Central pathology review of salivary gland adenoid cystic carcinoma. Head Neck. 42:1721–1727. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Grünmüller L, Thierauf J, Weissinger SE, Bergmann C, Bankfalvi A, Veit J, Hoffmann TK, Möller P and Lennerz JK: Biopanel identifies expression status of targetable proteins in sinonasal melanoma. Per Med. 13:291–301. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gu Z, Eils R and Schlesner M: Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 32:2847–2849. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Peng B and Chen X: Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res. 11:7334–7343. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Locati LD, Cavalieri S, Bergamini C, Resteghini C, Alfieri S, Calareso G, Bossi P, Perrone F, Tamborini E, Quattrone P, et al: Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. Head Neck. 41:3670–3676. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tchekmedyian V, Sherman EJ, Dunn L, Tran C, Baxi S, Katabi N, Antonescu CR, Ostrovnaya I, Haque SS, Pfister DG and Ho AL: Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 37:1529–1537. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu G, Zhang L, Dou S, Li R, Li J, Ye L, Jiang W, Dong M, Ruan M, Yang W and Zhang C: Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: A single-arm, phase II prospective study. Ther Adv Med Oncol. 13:175883592110136262021. View Article : Google Scholar : PubMed/NCBI | |
|
Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A and Levitt M: A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol. 43:33–36. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A and Siu LL: Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: A princess margaret hospital phase II consortium study. J Clin Oncol. 23:585–590. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Edwards PC, Bhuiya T and Kelsch RD: C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 95:586–593. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Vered M, Braunstein E and Buchner A: Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck. 24:632–636. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, Casieri P, Orsenigo M, Losa M, Bergamini C, et al: Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. Oral Oncol. 45:574–578. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM and Blumenschein GR Jr: Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 37:644–649. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ho AL, Dunn L, Sherman EJ, Fury MG, Baxi SS, Chandramohan R, Dogan S, Morris LG, Cullen GD, Haque S, et al: A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol. 27:1902–1908. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Laurie SA, Ho AL, Fury MG, Sherman E and Pfister DG: Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: A systematic review. Lancet Oncol. 12:815–824. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Locati LD, Galbiati D, Calareso G, Alfieri S, Singer S, Cavalieri S, Bergamini C, Bossi P, Orlandi E, Resteghini C, et al: Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. Cancer. 126:1888–1894. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Geiger JL, Ismaila N, Beadle B, Caudell JJ, Chau N, Deschler D, Glastonbury C, Kaufman M, Lamarre E, Lau HY, et al: Management of salivary gland malignancy: ASCO guideline. J Clin Oncol. 39:1909–1941. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
von Witzleben A, Müller-Richter U, Maurus K, Brändlein S, Theodoraki MN, Brunner C, Laban S, Lennerz J, Möller P, Hoffmann TK, et al: Protein-based oncopanel as addition to target sequencing in head and neck squamous cell carcinoma to individualize treatment decisions. Int J Mol Sci. 23:158352022. View Article : Google Scholar : PubMed/NCBI | |
|
Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, Masubuchi T, Matsuki T, Tani K, Osamura RY, et al: Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 37:125–134. 2019. View Article : Google Scholar : PubMed/NCBI |